Expression of ADAM-28 in Egyptian Adult Patients acute Lymphoblastic Leukemia Patients and its Relation to CNS Involvement

Abstract

dult acute lymphoblastic leukemia (ALL) accounts for approximately 15% to 20% of all adult acute leukemias. Overall, adults with ALL have a 60% to 80% chance or more of attaining first complete remission (CR1) using combination chemotherapy. However, many patients eventually relapse, particularly those with high-risk features such as age at diagnosis more than 35 years; white blood cell (WBC) count at diagnosis in excess of 30×109 /L (30 000/uL); non–T-cell phenotype; poor-risk cytogenetic abnormalities such as Philadelphia chromosome (Ph) positivity, t(4;11), or t(1;19); L2 or L3 phenotype; or failure to attain CR by ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zinc binding consensus sequence, and ADAM28 exhibits catalytic activity to a few substrates such as insulin-like growth factor binding protein-3.